An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (10 mg qd) as positive control, evaluating the efficacy, safety, tolerability of two fixed doses of SR58611A [amibegron] (175 mg q12/ 350 mg q12) in outpatients with major depressive disorder (MDD)

Trial Profile

An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (10 mg qd) as positive control, evaluating the efficacy, safety, tolerability of two fixed doses of SR58611A [amibegron] (175 mg q12/ 350 mg q12) in outpatients with major depressive disorder (MDD)

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Amibegron; Paroxetine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms SIRIUS
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2009 Actual patient number changed from 667 to 680 as reported by ClinicalTrials.gov.
    • 14 Sep 2008 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
    • 14 Sep 2008 Actual patient number (667) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top